Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobo Mintzer

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
International Psychogeriatrics|September 19, 2024
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|March 7, 2023
Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definitionMary Sano, Jeffrey Cummings, Stefanie Auer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 4, 2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 studyEmily D Clark, Jamie Perin, Nathan Herrmann, et al.
International Psychogeriatrics|January 31, 2025
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|October 15, 2014
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definitionJeffrey Cummings, Jacobo Mintzer, Henry Brodaty, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2019
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trialStephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, et al.
The Lancet. Neurology|December 25, 2003
Dementia with Lewy bodiesIan McKeith, Jacobo Mintzer, Dag Aarsland, et al.
International Psychogeriatrics|March 14, 2025
Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)Krushnaa Sankhe, Shankar Tumati, Jamie Perin, et al.
Journal of Geriatric Psychiatry and Neurology|January 10, 2012
Sertraline for the treatment of depression in Alzheimer disease: genetic influencesMatthew E Peters, Vijay Vaidya, Lea T Drye, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
International Psychogeriatrics|September 19, 2024
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|March 7, 2023
Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definitionMary Sano, Jeffrey Cummings, Stefanie Auer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 4, 2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 studyEmily D Clark, Jamie Perin, Nathan Herrmann, et al.
International Psychogeriatrics|January 31, 2025
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2Shankar Tumati, Nathan Herrmann, Jaime Perin, et al.
International Psychogeriatrics|October 15, 2014
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definitionJeffrey Cummings, Jacobo Mintzer, Henry Brodaty, et al.
JAMA Neurology|September 27, 2021
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical TrialJacobo Mintzer, Krista L Lanctôt, Roberta W Scherer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2019
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trialStephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, et al.
The Lancet. Neurology|December 25, 2003
Dementia with Lewy bodiesIan McKeith, Jacobo Mintzer, Dag Aarsland, et al.
International Psychogeriatrics|March 14, 2025
Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)Krushnaa Sankhe, Shankar Tumati, Jamie Perin, et al.
Journal of Geriatric Psychiatry and Neurology|January 10, 2012
Sertraline for the treatment of depression in Alzheimer disease: genetic influencesMatthew E Peters, Vijay Vaidya, Lea T Drye, et al.
Pageof 7